2019 novel coronavirus disease (COVID-19) is caused by the infection of severe acute respiratory syndrome novel coronavirus (SARS-CoV-2). It is characterized by substantial respiratory symptoms and complicated with widespread other organ injuries. Cardiovascular impairment is one of the notable extrapulmonary manifestations, in terms of the deterioration of pre-existing cardiovascular diseases and newly onset acute events. We hereby review the high-quality reports about cardiovascular involvement in COVID-19 and summarize the main clinical characteristics of cardiac relevance for the all the first line clinical physicians. Additionally, the possible underlying mechanisms and the rationale for the application of specific medications, such as renin-angiotensin-aldosterone system inhibitors and hydroxychloroquine are also discussed.
第一作者单位:[1]Wuhan Univ, Dept Cardiol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
通讯作者:
通讯机构:[2]Huazhong Univ Sci & Technol, Dept Internal Med, Div Cardiol, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
Li Chenze,Wang Dao Wen,Zhao Chunxia.Cardiovascular involvement in patients with 2019 novel coronavirus disease[J].JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE.2021,9(3):152-160.doi:10.2478/jtim-2021-0016.
APA:
Li, Chenze,Wang, Dao Wen&Zhao, Chunxia.(2021).Cardiovascular involvement in patients with 2019 novel coronavirus disease.JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE,9,(3)
MLA:
Li, Chenze,et al."Cardiovascular involvement in patients with 2019 novel coronavirus disease".JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE 9..3(2021):152-160